BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Ibrutinib readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Ibrutinib\, from ClinicalTrials.gov estim
 ates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT01479842-2041@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Ibrutinib: Phase 1 readout est. (NCT01479842)
DESCRIPTION:Ibrutinib\, phase 1\, Mantle Cell Lymphoma.\nStudy: Rituxan/Ben
 damustine/PCI-32765 in Relapsed DLBCL\, MCL\, or Indolent Non-Hodgkin's Ly
 mphoma\nEstimated primary completion: 1 December 2026. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/ibrutinib#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT01479842
URL:https://assetmemo.bio/drug/ibrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04421560-2041@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20261205
DTEND;VALUE=DATE:20261206
SUMMARY:Ibrutinib: Phase 1/2 readout est. (NCT04421560)
DESCRIPTION:Ibrutinib\, phase 1/2.\nStudy: Pembrolizumab\, Ibrutinib and Ri
 tuximab in PCNSL\nEstimated primary completion: 5 December 2026. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/ibrutinib#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT04421560
URL:https://assetmemo.bio/drug/ibrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03513562-2041@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Ibrutinib: Phase 2 readout est. (NCT03513562)
DESCRIPTION:Ibrutinib\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy: Ven
 etoclax and Ibrutinib in Treating in Participants With Chronic Lymphocytic
  Leukemia and Ibrutinib Resistance Mutations\nEstimated primary completion
 : 31 December 2026. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/i
 brutinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT03513562
URL:https://assetmemo.bio/drug/ibrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02436707-2041@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Ibrutinib: Phase 2 readout est. (NCT02436707)
DESCRIPTION:Ibrutinib\, phase 2.\nStudy: Novel Combination Therapy in the T
 reatment of Relapsed and Refractory Aggressive B-Cell Lymphoma\nEstimated 
 primary completion: 31 December 2026. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/ibrutinib#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT02436707
URL:https://assetmemo.bio/drug/ibrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01804686-2041@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Ibrutinib: Phase 3 readout est. (NCT01804686)
DESCRIPTION:Ibrutinib\, phase 3\, Diffuse Large B-Cell Lymphoma.\nStudy: A 
 Long-term Extension Study of PCI-32765 (Ibrutinib)\nEstimated primary comp
 letion: 31 December 2026. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/ibrutinib#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT01804686
URL:https://assetmemo.bio/drug/ibrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07923162-2041@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:Ibrutinib: Phase 4 readout est. (NCT07923162)
DESCRIPTION:Ibrutinib\, phase 4.\nStudy: MACE and BTK Inhibitors\nEstimated
  primary completion: 1 February 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/ibrutinib#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07923162
URL:https://assetmemo.bio/drug/ibrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02940301-2041@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20270215
DTEND;VALUE=DATE:20270216
SUMMARY:Ibrutinib: Phase 2 readout est. (NCT02940301)
DESCRIPTION:Ibrutinib\, phase 2.\nStudy: Ibrutinib and Nivolumab in Treatin
 g Patients With Relapsed or Refractory Classical Hodgkin Lymphoma\nEstimat
 ed primary completion: 15 February 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/ibrutinib#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT02940301
URL:https://assetmemo.bio/drug/ibrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03710772-2041@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20270322
DTEND;VALUE=DATE:20270323
SUMMARY:Ibrutinib: Phase 2 readout est. (NCT03710772)
DESCRIPTION:Ibrutinib\, phase 2\, Mantle Cell Lymphoma.\nStudy: Ibrutinib\,
  Rituximab\, Venetoclax\, and Combination Chemotherapy in Treating Patient
 s With Newly Diagnosed Mantle Cell Lymphoma\nEstimated primary completion:
  22 March 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ibrut
 inib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T03710772
URL:https://assetmemo.bio/drug/ibrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03153202-2041@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Ibrutinib: Phase 1/2 readout est. (NCT03153202)
DESCRIPTION:Ibrutinib\, phase 1/2\, Mantle Cell Lymphoma.\nStudy: Study to 
 Evaluate the Safety and Preliminary Efficacy of Ibrutinib and Pembrolizuma
 b in Patients With Chronic Lymphocytic Leukemia (CLL) or Mantle Cell Lymph
 oma (MCL)\nEstimated primary completion: April 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/ibrutinib#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT03153202
URL:https://assetmemo.bio/drug/ibrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04450173-2041@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Ibrutinib: Phase 2 readout est. (NCT04450173)
DESCRIPTION:Ibrutinib\, phase 2.\nStudy: Obinutuzumab\, Ibrutinib\, and Ven
 etoclax for the Treatment of Previously Untreated Stage II-IV Follicular L
 ymphoma\nEstimated primary completion: April 2027. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/ibrutinib#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT04450173
URL:https://assetmemo.bio/drug/ibrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03229200-2041@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20270510
DTEND;VALUE=DATE:20270511
SUMMARY:Ibrutinib: Phase 4 readout est. (NCT03229200)
DESCRIPTION:Ibrutinib\, phase 4.\nStudy: Extended Treatment Protocol for Su
 bjects Continuing to Benefit From Ibrutinib.\nEstimated primary completion
 : 10 May 2027. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ibruti
 nib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 03229200
URL:https://assetmemo.bio/drug/ibrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03128879-2041@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Ibrutinib: Phase 2 readout est. (NCT03128879)
DESCRIPTION:Ibrutinib\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy: Ven
 etoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL\nEstima
 ted primary completion: 31 May 2027. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/ibrutinib#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT03128879
URL:https://assetmemo.bio/drug/ibrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03697512-2041@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20270615
DTEND;VALUE=DATE:20270616
SUMMARY:Ibrutinib: Phase 2 readout est. (NCT03697512)
DESCRIPTION:Ibrutinib\, phase 2.\nStudy: MALIBU Trial - Combination of Ibru
 tinib and Rituximab in Untreated Marginal Zone Lymphomas\nEstimated primar
 y completion: 15 June 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/ibrutinib#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT03697512
URL:https://assetmemo.bio/drug/ibrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03960840-2041@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Ibrutinib: Phase 1/2 readout est. (NCT03960840)
DESCRIPTION:Ibrutinib\, phase 1/2\, Diffuse Large B-Cell Lymphoma.\nStudy: 
 Phase I/II Study of Rapcabtagene Autoleucel in CLL\, 3L+ DLBCL\, r/r ALL a
 nd 1L HR LBCL\nEstimated primary completion: 30 June 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/ibrutinib#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT03960840
URL:https://assetmemo.bio/drug/ibrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02427620-2041@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Ibrutinib: Phase 2 readout est. (NCT02427620)
DESCRIPTION:Ibrutinib\, phase 2\, Mantle Cell Lymphoma.\nStudy: Ibrutinib\,
  Rituximab\, and Consolidation Chemotherapy in Treating Young Patients Wit
 h Newly Diagnosed Mantle Cell Lymphoma\nEstimated primary completion: 30 J
 une 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ibrutinib#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT02427
 620
URL:https://assetmemo.bio/drug/ibrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03328078-2041@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Ibrutinib: Phase 1/2 readout est. (NCT03328078)
DESCRIPTION:Ibrutinib\, phase 1/2.\nStudy: CA-4948-101: Open-Label\, Dose E
 scalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refr
 actory Primary Central Nervous System Lymphoma (R/R PCNSL)\nEstimated prim
 ary completion: July 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/ibrutinib#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT03328078
URL:https://assetmemo.bio/drug/ibrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02756897-2041@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20270701
DTEND;VALUE=DATE:20270702
SUMMARY:Ibrutinib: Phase 2 readout est. (NCT02756897)
DESCRIPTION:Ibrutinib\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy: Ven
 etoclax and Ibrutinib in Treating Patients With Chronic or Small Lymphocyt
 ic Leukemia\nEstimated primary completion: 1 July 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/ibrutinib#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT02756897
URL:https://assetmemo.bio/drug/ibrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03223610-2041@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20270812
DTEND;VALUE=DATE:20270813
SUMMARY:Ibrutinib: Phase 1/2 readout est. (NCT03223610)
DESCRIPTION:Ibrutinib\, phase 1/2\, Diffuse Large B-Cell Lymphoma.\nStudy: 
 Venetoclax\, Ibrutinib\, Prednisone\, Obinutuzumab\, and Revlimid (ViPOR) 
 in Relapsed/Refractory B-cell Lymphoma\nEstimated primary completion: 12 A
 ugust 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ibrutinib
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT032
 23610
URL:https://assetmemo.bio/drug/ibrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05672173-2041@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20270824
DTEND;VALUE=DATE:20270825
SUMMARY:Ibrutinib: Phase 2 readout est. (NCT05672173)
DESCRIPTION:Ibrutinib\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy: Lis
 ocabtagene Maraleucel\, Nivolumab and Ibrutinib for the Treatment of Richt
 er's Transformation\nEstimated primary completion: 24 August 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/ibrutinib#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT05672173
URL:https://assetmemo.bio/drug/ibrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06536049-2041@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Ibrutinib: Phase 1/2 readout est. (NCT06536049)
DESCRIPTION:Ibrutinib\, phase 1/2\, Diffuse Large B-Cell Lymphoma.\nStudy: 
 Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Agg
 ressive B-Cell Non-Hodgkin Lymphoma\nEstimated primary completion: 31 Augu
 st 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/ibrutinib#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT065360
 49
URL:https://assetmemo.bio/drug/ibrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04608318-2041@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Ibrutinib: Phase 3 readout est. (NCT04608318)
DESCRIPTION:Ibrutinib\, phase 3.\nStudy: Ibrutinib Monotherapy Versus Fixed
 -duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plu
 s Venetoclax in Patients With Previously Untreated Chronic Lymphocytic Leu
 kaemia (CLL)\nEstimated primary completion: September 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/ibrutinib#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT04608318
URL:https://assetmemo.bio/drug/ibrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04234061-2041@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:Ibrutinib: Phase 2 readout est. (NCT04234061)
DESCRIPTION:Ibrutinib\, phase 2\, Mantle Cell Lymphoma.\nStudy: Clinical Tr
 ial to Assess The Efficacy and Safety of the Combination of Tisagenlecleuc
 el And Ibrutinib in Mantle Cell Lymphoma\nEstimated primary completion: 1 
 September 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ibrut
 inib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T04234061
URL:https://assetmemo.bio/drug/ibrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06357676-2041@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20271101
DTEND;VALUE=DATE:20271102
SUMMARY:Ibrutinib: Phase 1/2 readout est. (NCT06357676)
DESCRIPTION:Ibrutinib\, phase 1/2\, Mantle Cell Lymphoma.\nStudy: Glofitama
 b Plus Ibrutinib With Obinutuzumab for the Treatment of Patients With Mant
 le Cell Lymphoma\, IGNITE MCL Trial\nEstimated primary completion: 1 Novem
 ber 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ibrutinib#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06357
 676
URL:https://assetmemo.bio/drug/ibrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03331198-2041@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20271126
DTEND;VALUE=DATE:20271127
SUMMARY:Ibrutinib: Phase 1/2 readout est. (NCT03331198)
DESCRIPTION:Ibrutinib\, phase 1/2\, Chronic Lymphocytic Leukemia.\nStudy: S
 tudy Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed o
 r Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymph
 oma (SLL)\nEstimated primary completion: 26 November 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/ibrutinib#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT03331198
URL:https://assetmemo.bio/drug/ibrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06958705-2041@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:Ibrutinib: Phase 2 readout est. (NCT06958705)
DESCRIPTION:Ibrutinib\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy: Ven
 etoclax as Consolidation in CLL Patients Treated With BTK Inhibitor Monoth
 erapy\nEstimated primary completion: 1 December 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/ibrutinib#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT06958705
URL:https://assetmemo.bio/drug/ibrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05963074-2041@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20271215
DTEND;VALUE=DATE:20271216
SUMMARY:Ibrutinib: Phase 2 readout est. (NCT05963074)
DESCRIPTION:Ibrutinib\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy: A S
 tudy to Customize Ibrutinib Treatment Regimens for Participants With Previ
 ously Untreated Chronic Lymphocytic Leukemia\nEstimated primary completion
 : 15 December 2027. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/i
 brutinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT05963074
URL:https://assetmemo.bio/drug/ibrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06788509-2041@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20280119
DTEND;VALUE=DATE:20280120
SUMMARY:Ibrutinib: Phase 1 readout est. (NCT06788509)
DESCRIPTION:Ibrutinib\, phase 1.\nStudy: A Rollover Study for Continued Stu
 dy Treatment and Ongoing Safety Monitoring\nEstimated primary completion: 
 19 January 2028. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ibru
 tinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT06788509
URL:https://assetmemo.bio/drug/ibrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03282396-2041@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20280228
DTEND;VALUE=DATE:20280229
SUMMARY:Ibrutinib: Phase 2 readout est. (NCT03282396)
DESCRIPTION:Ibrutinib\, phase 2\, Mantle Cell Lymphoma.\nStudy: Ibrutinib i
 n Treating Participants With Untreated High Risk Smoldering Mantle Cell Ly
 mphoma\nEstimated primary completion: 28 February 2028. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/ibrutinib#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT03282396
URL:https://assetmemo.bio/drug/ibrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05106296-2041@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20280330
DTEND;VALUE=DATE:20280331
SUMMARY:Ibrutinib: Phase 1 readout est. (NCT05106296)
DESCRIPTION:Ibrutinib\, phase 1.\nStudy: Chemo-immunotherapy Using Ibrutini
 b Plus Indoximod for Patients With Pediatric Brain Cancer\nEstimated prima
 ry completion: 30 March 2028. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/ibrutinib#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT05106296
URL:https://assetmemo.bio/drug/ibrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02629809-2041@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Ibrutinib: Phase 2 readout est. (NCT02629809)
DESCRIPTION:Ibrutinib\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy: Ibr
 utinib\, Fludarabine Phosphate\, Cyclophosphamide\, and Obinutuzumab in Tr
 eating Patients With Chronic Lymphocytic Leukemia\nEstimated primary compl
 etion: 31 March 2028. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /ibrutinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT02629809
URL:https://assetmemo.bio/drug/ibrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04263480-2041@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Ibrutinib: Phase 2 readout est. (NCT04263480)
DESCRIPTION:Ibrutinib\, phase 2.\nStudy: Efficacy and Safety of Carfilzomib
  in Combination With Ibrutinib vs Ibrutinib in Waldenström's Macroglobuli
 nemia\nEstimated primary completion: May 2028. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/ibrutinib#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT04263480
URL:https://assetmemo.bio/drug/ibrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03701282-2041@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20280507
DTEND;VALUE=DATE:20280508
SUMMARY:Ibrutinib: Phase 3 readout est. (NCT03701282)
DESCRIPTION:Ibrutinib\, phase 3\, Chronic Lymphocytic Leukemia.\nStudy: Ass
 essing the Ability of Combination Treatment With Venetoclax to Permit Time
  Limited Therapy in Chronic Lymphocytic Leukemia\nEstimated primary comple
 tion: 7 May 2028. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ibr
 utinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT03701282
URL:https://assetmemo.bio/drug/ibrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05998642-2041@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Ibrutinib: Phase 2 readout est. (NCT05998642)
DESCRIPTION:Ibrutinib\, phase 2.\nStudy: Ibrutinib Combination Therapy in T
 ransplant Ineligible Individuals With Newly Diagnosed Primary CNS Lymphoma
 \nEstimated primary completion: 31 May 2028. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/ibrutinib#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT05998642
URL:https://assetmemo.bio/drug/ibrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02007044-2041@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Ibrutinib: Phase 2 readout est. (NCT02007044)
DESCRIPTION:Ibrutinib\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy: Ibr
 utinib With or Without Rituximab in Treating Patients With Relapsed Chroni
 c Lymphocytic Leukemia\nEstimated primary completion: 30 June 2028. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/ibrutinib#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT02007044
URL:https://assetmemo.bio/drug/ibrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01880567-2041@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Ibrutinib: Phase 2 readout est. (NCT01880567)
DESCRIPTION:Ibrutinib\, phase 2\, Mantle Cell Lymphoma.\nStudy: Ibrutinib a
 nd Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell 
 Lymphoma or Older Patients With Newly Diagnosed Mantle Cell Lymphoma\nEsti
 mated primary completion: 31 July 2028. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/ibrutinib#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT01880567
URL:https://assetmemo.bio/drug/ibrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07082868-2041@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Ibrutinib: Phase 1 readout est. (NCT07082868)
DESCRIPTION:Ibrutinib\, phase 1.\nStudy: A Study of Epcoritamab and Ibrutin
 ib in People With Central Nervous System Lymphoma (CNSL)\nEstimated primar
 y completion: August 2028. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/ibrutinib#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07082868
URL:https://assetmemo.bio/drug/ibrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07169565-2041@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20280901
DTEND;VALUE=DATE:20280902
SUMMARY:Ibrutinib: Phase 1 readout est. (NCT07169565)
DESCRIPTION:Ibrutinib\, phase 1.\nStudy: Ibrutinib Followed by BR (Bendamus
 tine and Rituximab) as a Time-Limited Therapy for Waldenström Macroglobul
 inemia\nEstimated primary completion: 1 September 2028. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/ibrutinib#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07169565
URL:https://assetmemo.bio/drug/ibrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06649812-2041@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20280901
DTEND;VALUE=DATE:20280902
SUMMARY:Ibrutinib: Phase 2 readout est. (NCT06649812)
DESCRIPTION:Ibrutinib\, phase 2\, Diffuse Large B-Cell Lymphoma.\nStudy: Te
 sting the Effectiveness of a Combination Targeted Therapy (ViPOR) for Pati
 ents With Relapsed and/or Refractory Aggressive B-cell Lymphoma\nEstimated
  primary completion: 1 September 2028. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/ibrutinib#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT06649812
URL:https://assetmemo.bio/drug/ibrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07052695-2041@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Ibrutinib: Phase 1/2 readout est. (NCT07052695)
DESCRIPTION:Ibrutinib\, phase 1/2\, Chronic Lymphocytic Leukemia.\nStudy: M
 osunetuzumab for CLL MRD Clearance\nEstimated primary completion: 31 Decem
 ber 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ibrutinib#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07052
 695
URL:https://assetmemo.bio/drug/ibrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03964090-2041@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Ibrutinib: Phase 2 readout est. (NCT03964090)
DESCRIPTION:Ibrutinib\, phase 2.\nStudy: Temozolomide\, Etoposide\, Doxil\,
  Dexamethasone\, Ibrutinib\, and Rituximab (TEDDI-R) in Aggressive B-cell 
 Lymphomas With Secondary Involvement of the Central Nervous System (CNS)\n
 Estimated primary completion: 31 December 2028. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/ibrutinib#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT03964090
URL:https://assetmemo.bio/drug/ibrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07738887-2041@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Ibrutinib: Phase 2 readout est. (NCT07738887)
DESCRIPTION:Ibrutinib\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy: Epc
 oritamab Plus Venetoclax Plus Ibrutinib in Patients With Chronic Lymphocyt
 ic Leukemia With TP53 Alterations\nEstimated primary completion: 31 Decemb
 er 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/ibrutinib#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT077388
 87
URL:https://assetmemo.bio/drug/ibrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01841723-2041@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Ibrutinib: Phase 2 readout est. (NCT01841723)
DESCRIPTION:Ibrutinib\, phase 2.\nStudy: Ibrutinib in Treating Patients Wit
 h Relapsed Hairy Cell Leukemia\nEstimated primary completion: 31 December 
 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/ibrutinib#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT01841723
URL:https://assetmemo.bio/drug/ibrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04061512-2041@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20300331
DTEND;VALUE=DATE:20300401
SUMMARY:Ibrutinib: Phase 2/3 readout est. (NCT04061512)
DESCRIPTION:Ibrutinib\, phase 2/3.\nStudy: Rituximab and Ibrutinib (RI) Ver
 sus Dexamethasone\, Rituximab and Cyclophosphamide (DRC) as Initial Therap
 y for Waldenström's Macroglobulinaemia\nEstimated primary completion: Mar
 ch 2030. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/ibrutinib#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT040615
 12
URL:https://assetmemo.bio/drug/ibrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05283720-2041@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20321130
DTEND;VALUE=DATE:20321201
SUMMARY:Ibrutinib: Phase 2 readout est. (NCT05283720)
DESCRIPTION:Ibrutinib\, phase 2.\nStudy: A Study to Evaluate Adverse Events
  and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combin
 ation With Oral and Intravenous Anti-Neoplastic Agents in Adult Participan
 ts With Non-Hodgkin Lymphoma\nEstimated primary completion: November 2032.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/ibrutinib#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT05283720
URL:https://assetmemo.bio/drug/ibrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04446962-2041@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20350202
DTEND;VALUE=DATE:20350203
SUMMARY:Ibrutinib: Phase 1/2 readout est. (NCT04446962)
DESCRIPTION:Ibrutinib\, phase 1/2.\nStudy: LOC-R01 Study of Lenalidomide an
 d Ibrutinib in Association With Rituximab-Methotrexate Procarbazine Vincri
 stin (R-MPV)\nEstimated primary completion: 2 February 2035. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/ibrutinib#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT04446962
URL:https://assetmemo.bio/drug/ibrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07474961-2041@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20361231
DTEND;VALUE=DATE:20370101
SUMMARY:Ibrutinib: Phase 4 readout est. (NCT07474961)
DESCRIPTION:Ibrutinib\, phase 4.\nStudy: BLOOD-dose: A Platform Trial Evalu
 ating Dose Optimization in Hematological Diseases.\nEstimated primary comp
 letion: December 2036. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/ibrutinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07474961
URL:https://assetmemo.bio/drug/ibrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
